Skip to main content

Xilio Therapeutics, Inc.

XLO
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001840233

No open-market purchases or sales by Xilio Therapeutics, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $32.6M in total; no superinvestor holds it.

Holders of 5% or more of XLO

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Xilio Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of XLO
HolderLatest formStakeChangeFirst filedLatest filingFiling
Gilead Sciences, Inc.13G/A19.90%14.5M shares0.00 ppfrom 19.90%Apr 5, 20244 filingsFeb 12, 2026SEC
Coastlands Capital LP13G9.99%5.35M sharesNewDec 11, 20251 filingDec 11, 2025SEC
Coastlands Capital LP13G/A9.99%731.6K shares–Nov 13, 20261 filingNov 13, 2026SEC
Logos Global Management LP13G9.99%730.3K sharesNewNov 16, 20261 filingNov 16, 2026SEC
Bain Capital Life Sciences Fund II, L.P.13G/A9.99%664.0K shares–May 15, 20261 filingMay 15, 2026SEC
OrbiMed Advisors LLC13G9.99%642.0K sharesNewMay 15, 20261 filingMay 15, 2026SEC
Sirenia Capital Management LP13G9.90%1.14M sharesNewMay 15, 20261 filingMay 15, 2026SEC
StemPoint Capital LP13G/A9.50%628.9K shares+1.10 ppfrom 8.40%Nov 14, 20253 filingsAug 14, 2026SEC
ADAR1 Capital Management, LLC13G9.30%381.0K sharesNewNov 16, 20261 filingNov 16, 2026SEC
AbbVie Inc.13G9.00%4.35M sharesNewFeb 18, 20251 filingFeb 18, 2025SEC
Bain Capital Life Sciences Fund II, L.P.13G/A8.50%6.26M shares–Nov 5, 20214 filingsFeb 17, 2026SEC
Adage Capital Management, L.P.13G7.06%464.6K sharesNewNov 12, 20261 filingNov 12, 2026SEC
Frazier Life Sciences Public Fund, L.P.13G/A6.70%4.68M shares−3.20 ppfrom 9.90%Jun 12, 20253 filingsFeb 13, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

51 Schedule 13D and 13G filings on Xilio Therapeutics, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on XLO
Filed (ET)FilerFormStakeChangeEvent dateFiling
Nov 16, 20269:56 PM ETADAR1 Capital Management, LLCand 1 other13G9.30%381.0K sharesNewSep 30, 2025SEC
Nov 16, 20265:12 PM ETLogos Global Management LPand 5 others13G9.99%730.3K sharesNewJun 5, 2025SEC
Nov 13, 20269:22 PM ETCoastlands Capital LPand 4 others13G/A9.99%731.6K shares–Sep 30, 2026SEC
Nov 12, 20269:01 AM ETAdage Capital Management, L.P.and 2 others13G7.06%464.6K sharesNewSep 30, 2026SEC
Aug 14, 202612:01 PM ETStemPoint Capital LPand 2 others13G/A9.50%628.9K shares+1.10 ppfrom 8.40%Jun 30, 2026SEC
May 15, 20264:38 PM ETOrbiMed Advisors LLCand 1 other13G9.99%642.0K sharesNewMar 31, 2026SEC
May 15, 20264:30 PM ETBain Capital Life Sciences Fund II, L.P.and 2 others13G/A9.99%664.0K shares–Mar 31, 2026SEC
May 15, 20264:24 PM ETPoint72 Asset Management, L.P.and 2 others13G/A0.00%0 shares−9.90 ppfrom 9.90%Below 5%Mar 31, 2026SEC
May 15, 20268:06 AM ETSirenia Capital Management LPand 1 other13G9.90%1.14M sharesNewMar 31, 2026SEC
Feb 17, 20264:30 PM ETBain Capital Life Sciences Fund II, L.P.and 3 others13G/A8.50%6.26M shares–Dec 31, 2025SEC
Feb 17, 202610:00 AM ETStemPoint Capital LPand 2 others13G/A8.40%6.03M shares+1.20 ppfrom 7.20%Dec 31, 2025SEC
Feb 13, 20265:31 PM ETFrazier Life Sciences Public Fund, L.P.and 13 others13G/A6.70%4.68M shares−3.20 ppfrom 9.90%Dec 31, 2025SEC
Feb 12, 20264:39 PM ETGilead Sciences, Inc.13G/A19.90%14.5M shares0.00 ppfrom 19.90%Dec 31, 2025SEC
Dec 11, 20255:55 PM ETCoastlands Capital LPand 4 others13G9.99%5.35M sharesNewDec 4, 2025SEC
Nov 14, 20254:02 PM ETPoint72 Asset Management, L.P.and 2 others13G/A9.90%8.00M shares+2.70 ppfrom 7.20%Sep 30, 2025SEC
Nov 14, 202510:00 AM ETStemPoint Capital LPand 2 others13G7.20%4.00M sharesNewSep 30, 2025SEC
Aug 14, 20254:42 PM ETGilead Sciences, Inc.13G/A19.90%10.6M shares0.00 ppfrom 19.90%Jun 30, 2025SEC
Aug 14, 20251:47 PM ETFrazier Life Sciences Public Fund, L.P.and 19 others13G/A9.90%8.14M shares0.00 ppfrom 9.90%Jun 30, 2025SEC
Jun 17, 20255:28 PM ETPoint72 Asset Management, L.P.and 2 others13G7.20%4.00M sharesNewJun 5, 2025SEC
Jun 12, 20254:55 PM ETFrazier Life Sciences Public Fund, L.P.and 19 others13G9.90%5.75M sharesNewJun 5, 2025SEC
May 15, 202510:48 AM ETRock Springs Capital Management LPand 4 others13G/A0.00%0 shares–Below 5%Mar 31, 2025SEC
Feb 18, 20254:15 PM ETAbbVie Inc.13G9.00%4.35M sharesNewFeb 11, 2025SEC
Dec 19, 20244:15 PM ETGilead Sciences, Inc.13G/A19.90%9.11M shares–Dec 18, 2024SEC
Nov 14, 2024Bain Capital Life Sciences Fund II, L.P.13G/AOld format–––SEC
Nov 14, 2024Atlas Venture Fund XI, L.P.13G/AOld format–––SEC
Nov 12, 2024Rock Springs Capital Management LP13G/AOld format–––SEC
Nov 12, 2024FMR LLC13G/AOld format–––SEC
Sep 27, 2024GKCC, LLC13GOld format–New–SEC
Jul 31, 2024Takeda Pharmaceutical Co Ltd13G/AOld format–––SEC
Apr 5, 2024Gilead Sciences, Inc.13GOld format–New–SEC
Apr 5, 2024Rock Springs Capital Management LP13G/AOld format–––SEC
Feb 14, 2024Rock Springs Capital Management LP13GOld format–New–SEC
Feb 6, 2024Octagon Capital Advisors LP13G/AOld format–––SEC
Feb 5, 2024Octagon Capital Advisors LP13G/AOld format–––SEC
Apr 10, 2023MRL Ventures Fund LLC13GOld format–New–SEC
Feb 9, 2023FMR LLC13G/AOld format–––SEC
Jan 25, 2023Octagon Capital Advisors LP13GOld format–New–SEC
Dec 29, 2022Flynn James E13G/AOld format–––SEC
Nov 14, 2022Ra Capital Management, L.P.13G/AOld format–––SEC
Feb 14, 2022Bain Capital Life Sciences Fund II, L.P.13G/AOld format–––SEC
Feb 14, 2022Ra Capital Management, L.P.13G/AOld format–––SEC
Feb 11, 2022Flynn James E13G/AOld format–––SEC
Feb 9, 2022FMR LLC13G/AOld format–––SEC
Jan 14, 2022Takeda Pharmaceutical Co Ltd13GOld format–New–SEC
Nov 5, 2021Atlas Venture Fund XI, L.P.13GOld format–New–SEC
Nov 5, 2021Bain Capital Life Sciences Fund II, L.P.13GOld format–New–SEC
Nov 5, 2021RiverVest Venture Fund IV, L.P.13DOld format–New–SEC
Nov 5, 2021Ra Capital Management, L.P.13GOld format–New–SEC
Nov 4, 2021FMR LLC13GOld format–New–SEC
Nov 3, 2021SV7 Impact Medicine Fund LP13DOld format–New–SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Xilio Therapeutics, Inc. shares.

No Form 144 notices for Xilio Therapeutics, Inc. are on file.